



University of Dundee

Treatment approaches in immunosuppressed patients with advanced cutaneous squamous cell carcinoma

Willenbrink, T. J.; Jambusaria-Pahlajani, A.; Arron, S.; Seckin, D.; Harwood, C. A.; Proby, C. M.

Published in:
Journal of the European Academy of Dermatology and Venereology

DOI:
[10.1111/jdv.15843](https://doi.org/10.1111/jdv.15843)

Publication date:
2019

Document Version
Peer reviewed version

[Link to publication in Discovery Research Portal](#)

Citation for published version (APA):
Willenbrink, T. J., Jambusaria-Pahlajani, A., Arron, S., Seckin, D., Harwood, C. A., & Proby, C. M. (2019). Treatment approaches in immunosuppressed patients with advanced cutaneous squamous cell carcinoma. *Journal of the European Academy of Dermatology and Venereology*, 33(S8), 57-60. <https://doi.org/10.1111/jdv.15843>

General rights

Copyright and moral rights for the publications made accessible in Discovery Research Portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Treatment approaches in immunosuppressed patients with advanced cutaneous squamous cell carcinoma

T.J. Willenbrink¹, A. Jambusaria-Pahlajani¹, S. Arron², D. Seckin³, C.A. Harwood⁴, C.M. Proby^{5*}

¹Division of Dermatology, Department of Internal Medicine, The University of Texas at Austin-Dell Medical School, Austin, Texas, USA

²Department of Dermatology, University of California, San Francisco

³Department of Dermatology, Baskent University Faculty of Medicine Ankara, Turkey

⁴Centre for Cell Biology and Cutaneous Research, Blizard Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, 4 Newark Street, London UK

⁵Division of Molecular and Clinical Medicine, School of Medicine, University of Dundee, Ninewells Hospital, Dundee, DD1 9SY, UK

*Correspondence: Charlotte Proby: Email: c.proby@dundee.ac.uk

Conflict of interest

None.

Funding Source

None.

Abstract

Immunosuppression, both iatrogenic and disease-related, is associated with a greatly increased incidence of cutaneous SCC (cSCC) and with aggressive cSCC and worse disease outcomes. Consequently, rapid access to skin cancer services and prudent surgical choices, such as circumferential margin assessment, are essential when treating advanced cSCC in an immunosuppressed (IS) patient. For high-risk cancers and for control of cSCC multiplicity, additional strategies should be actively considered within the multidisciplinary clinical care team. These include minimisation or revision of immunosuppressive medications, systemic chemoprevention (including retinoids, nicotinamide, capecitabine) and adjuvant therapies

such as radiotherapy. Unfortunately, there is a relative paucity of good evidence for many of these treatments in the IS. Systemic treatments for metastatic cSCC are often contraindicated in organ transplant recipients, notably checkpoint inhibitor immunotherapy. There are also toxicity concerns with some conventional chemotherapies and EGFR inhibitors. Until recently, clinical trials have largely excluded immunosuppressed individuals. Development of more effective treatment for advanced cSCC in this high-risk group and prospective clinical trials are now research priorities.

Introduction

Immunosuppression (IS) is a strong risk factor for the development of cutaneous SCC (cSCC). cSCC are frequently multiple and disease-related outcomes are significantly worse in organ transplant recipients (OTR) and patients with haematological malignancies^{1,2,3}. Loco-regional recurrence is more common⁴ and a recent national UK study found that IS doubles the risk of metastatic cSCC⁵. This review will address the specific challenges of managing advanced cSCC in the context of immunosuppression, including specific surgical considerations, use of radiotherapy as primary and adjuvant treatment, and barriers to use of conventional chemotherapies, targeted agents and immunotherapies such as immune checkpoint inhibitors (ICI)^{6,7}. Tertiary strategies to reduce risk involving alterations in immunosuppressive drugs and chemoprevention will also be outlined. Prospective clinical trials are now urgently needed to inform future improvements in treatment choices and standards of care.

Surgical Considerations in immunosuppressed patients with advanced cSCC

Complete surgical resection is central to primary disease control in immunosuppressed patients and Mohs surgery or complete circumferential peripheral and deep margin assessment is recommended. Certain immunosuppressed patient groups have a higher rate of subclinical margin extension, suggesting that Mohs surgery or other intraoperative margin assessment may be preferable^{8,9,10}, but this has yet to be tested in a prospective, randomised surgical trials.

Limited data exist on the risk of postoperative complications in immunosuppressed patients undergoing surgery. Some but not all studies report increased rates of post-operative wound infection compared to immunocompetent subjects. This may be confounded by the propensity to put immunosuppressed patients on antibiotic prophylaxis¹¹. Larger, prospective studies are needed to determine infection rates and the benefit of prophylaxis, if any.

While there is an increased risk of surgical dehiscence in patients on sirolimus¹², the morbidity associated with skin dehiscence is low enough that most dermatologic surgeons will not stop sirolimus for primary skin cancer excision. Invasive procedures such as lymphadenectomy may require transition from sirolimus onto another agent. This needs to be balanced against the benefits of switching a patient with cSCC from calcineurin inhibitors (CNI) to sirolimus, in order to reduce disease burden.

Thus, significant gaps exist in our understanding of surgical management of immunosuppressed patients with advanced cSCC. Future studies should focus on the benefits of intraoperative margin assessment in achieving complete clearance, risks of postoperative complications and the benefit of prophylactic intervention and postoperative adjuvant therapies such as radiotherapy.

Radiotherapy

Primary radiotherapy is not a first-line option in most OTR with cSCC. OTR tend to be younger and more likely to develop multiple tumours at specific anatomic sites, and previous radiotherapy to a particular site will usually preclude its subsequent use. Nonetheless, radiotherapy is an important strategy where surgery is not feasible or involved margins cannot be easily managed surgically. Death from cSCC usually results from uncontrolled loco-regional recurrence which is especially true for immunosuppressed individuals who are more likely to develop aggressive cSCC characterised by a high rate of loco-regional relapse¹. Combined treatment with surgery and radiotherapy is considered best practice for patients with cSCC metastatic to lymph nodes¹³. There are no prospective randomised trials testing the benefit of adjuvant radiotherapy, but retrospective reviews consistently report improved disease-free and overall survival in those where surgery was

combined with adjuvant radiotherapy to the nodal basins. The worse outcomes in immunosuppressed patients mandate a lower threshold for combined surgery and adjuvant radiotherapy, although each case should be considered on balance of benefits (reduced loco-regional recurrence rate) versus potential carcinogenesis (uncertain risk).

Minimisation of immunosuppression, switch to mTOR inhibitors, systemic retinoids, capecitabine and nicotinamide

Non-surgical strategies to minimize the incidence of cSCC in high-risk OTR include revision of immunosuppressive medications and use of chemoprevention. In order to prevent graft rejection in OTR, immunosuppressive drug regimens primarily include anti-proliferative agents (e.g. mycophenolate mofetil [MMF]), CNI (e.g. tacrolimus, cyclosporine) and prednisone¹⁴. Reduction or revision of immunosuppressive drugs is generally advised in OTR with a history of aggressive or multiple cSCC¹⁵. In these high-risk OTR, IS should be maintained at the lowest level compatible with adequate graft function¹⁶, limiting multi-drug regimens whenever possible¹⁵.

IS also has varying degrees of direct carcinogenic potential. Azathioprine, for example, is associated with both an increased incidence and the potential to develop more aggressive cSCC in OTR¹⁷. Carcinogenic potential of MMF is significantly lower than azathioprine; hence transition from azathioprine to MMF is recommended for high-risk patients¹⁶.

Another approach to reducing the risk of cSCC in high-risk patients is to transition from a CNI to an mTOR inhibitor (sirolimus or everolimus). CNI, through an increase in VEGF and TGF- β , can increase the rate of invasion and metastasis¹⁶. Although the full immunologic sequela of mTOR inhibition is not fully understood, these medications might have antineoplastic effects secondary to decreased tumour angiogenesis¹⁶. The rate of cSCC in patients treated with mTOR inhibitors is significantly reduced compared with calcineurin inhibitors. In one study of 120 kidney recipients with a history of at least one cSCC, patients treated with sirolimus were significantly less likely to develop cSCC compared to those treated with CNI (22% versus 39%, $p=0.02$)¹⁸. An additional study of 155 kidney recipients with a history of at least one cSCC demonstrated a 50% reduction in the rate of cSCC after one year¹⁹. Both studies had a high rate of drug discontinuation due to adverse effects^{18,19},

but doses used in these early studies were arguably too high. Five-year results show a maintained benefit with mTOR inhibition provided the switch was conducted in early, not advanced, carcinogenesis²⁰.

Acitretin is the main chemoprophylactic retinoid for OTR at high-risk of SCC. Criteria for starting acitretin include multiple cSCCs [e.g. >2-5 per year]; a single cSCC with high metastatic risk; or a locally-recurrent or metastatic cSCC. Low-dose acitretin (0.2-0.4 mg/kg/day for a minimum of 12 months) reduced cSCC development in high-risk OTR in the first three years of treatment²¹. Regimens vary, but acitretin is often started at a low dose (e.g. 10 mg every other day) with the dose increased every 4 weeks according to side effects until a final dose (e.g. 20-25 mg daily) is reached²². Adverse effects which may limit use or result in discontinuation include muco-cutaneous changes such as cheilitis, hair loss and nail splitting. Fasting lipids and liver function tests should be checked monthly as the dose is increased, and every 3 months once stable and creatinine should be monitored in impaired renal function. Life-long treatment is necessary for maintenance of cSCC suppression and rebound cSCC development upon discontinuation is well recognised²².

Capecitabine is another option in OTR with multiple cSCC. Capecitabine, a prodrug of 5-deoxy5-fluorouridine, is enzymatically converted to its active form, 5-fluorouracil in the liver^{23,24}. Low dose capecitabine has been effective in reducing the incidence of cSCC in OTR in some case series: for example, capecitabine 0.5 to 1.5 g/m² was associated with a 68% reduction in cSCC per month over one year²⁴. Side effects were diarrhoea, stomatitis, neutropenic fever, hand-foot syndrome, and gout^{15,23}. Before treatment, screening for dihydropyrimidine dehydrogenase deficiency is required as capecitabine can cause severe toxicity in these patients¹⁵.

More recently nicotinamide has shown benefit in reducing cSCC risk²⁵. It both reduces UV radiation-induced immunosuppression and enhances DNA repair²⁵. It has a favourable safety profile and is available over-the-counter²⁵. In a phase III trial of immunocompetent individuals, nicotinamide 500mg twice daily reduced the development of cSCC by 30% at 1 year²⁵. A phase II trial of 22 kidney recipients suggested a non-significant reduction in new cSCC²⁶. An RCT is currently ongoing in Australia.

Conventional chemotherapy and targeted therapy

Data regarding the use of both conventional chemotherapy and targeted therapy with EGFR inhibitors in immunosuppressed individuals are limited. Specific considerations include dose adjustments with organ dysfunction, side effects and drug interactions²⁷. For example, platinum compounds (e.g. cisplatin, carboplatin) cause myelosuppression and nephrotoxicity, and dose adjustments are required in renal impairment. Antimetabolite pyrimidine analogues (e.g. 5-fluorouracil, capecitabine) are myelosuppressive, associated with coronary artery vasospasm and dose adjustments are needed in liver impairment. Taxanes (e.g. paclitaxel) are myelosuppressive, require dose adjustments for liver impairment, and caution is required with concomitant use of CYP3A4 inhibitors/inducers (e.g. antiretrovirals such as ritonavir, saquinavir, nelfinavir and efavirenz) and P-glycoprotein inhibitors (e.g. CNI, ritonavir and saquinavir). Data on use of anti-EGFR inhibitors (e.g. cetuximab) are limited. Although generally well-tolerated, neutropenia, infection, liver dysfunction and sudden cardiac arrest²⁷ have been observed. Fatal diffuse alveolar damage in two lung transplant recipients on cetuximab, necessitate the use of EGFR inhibitors with extreme caution in this group²⁸.

Immunotherapy

Use of checkpoint inhibitor immunotherapy for immunosuppressed patients with advanced cSCC are restricted to case reports and case series⁶. Specific considerations include the potential risk of graft rejection; relevant immune-related adverse events on graft function, e.g. acute interstitial nephritis; possible reduced anti-tumour activity in the presence of immunosuppressive drugs and HIV; and effects on replication of HIV and hepatitis B/C viruses. Recent evidence - much of it from experience in advanced melanoma - suggests that the PD-1/PD-L1 axis is critical for maintaining organ tolerance whereas CTLA-4 blockade after induction of graft tolerance does not appear to affect allograft survival and this is reflected in rates of graft rejection which may be higher with anti PD-1/PD-L1 immunotherapy^{6,7,29,30}. Although limited data in melanoma also suggest rates of response may be comparable in OTRs and immunocompetent individuals, the contribution to graft rejection of reduction of immunosuppression in this context has been raised²⁹. Clinical trials are urgently required.

Retransplantation

Recent evidence suggests that the risk of cSCC increases with retransplantation, and these cSCC may be aggressive and associated with high mortality. In a multicentre retrospective study of 53 patients with previous post-transplant cSCC who received a second transplant, further cSCC developed in 74% of OTR after retransplantation. A higher proportion of these cSCC were histologically aggressive (26.4% versus 9.4% after the first transplant), and metastatic cSCC occurred in 10 patients of whom 5 died. Contributing to this risk were the older age and increased duration of IS, both known risk factors for aggressive SCC, and also use of azathioprine and T-cell depleting antibodies. Conversely, five patients in this series were retransplanted after an aggressive SCC, and this did not recur after the second transplantation suggesting that a history of aggressive SCC may not necessarily preclude retransplantation³¹.

Conclusions

Advanced cSCC are more frequent and more challenging to treat in immunosuppressed patients. Furthermore, this is an area with very few robust data to guide decision-making. Consequently, consensus and sharing of best practice underpin current treatment strategies in this context. Alternatives to checkpoint inhibitors are required for OTR and this needs to become an area of active scientific and clinical endeavour. In the meantime, the mainstay of management must be prevention, including patient education, photoprotection, skin surveillance and aggressive treatment of pre-cancerous actinic keratoses and field cancerisation.

References:

1. Martinez JC, Otley CC, Stasko T, et al. Defining the clinical course of metastatic skin cancer in organ transplant recipients. A multicentre collaborative study. *Arch Dermatol* 2003; 139: 301-6
2. Mehrany K, Weenig RH, Lee KK, et al. Increased metastasis and mortality from cutaneous squamous cell carcinoma in patients with chronic lymphocytic leukemia. *J Am Acad Dermatol* 2005; 53: 1067-71
3. Thompson AK, Kelley BF, Prokop LJ, Murad MH, Baum CL. Risk Factors for Cutaneous Squamous Cell Carcinoma Recurrence, Metastasis, and Disease-Specific Death: A Systematic Review and Meta-analysis. *JAMA Dermatol* 2016; 152(4): 419-28
4. Manyam BV, Garsa AA, Chin R-I, et al. A multi-institutional comparison of outcomes of immunosuppressed and immunocompetent patients treated with surgery and radiation therapy for cutaneous squamous cell carcinoma of the head and neck. *Cancer* 2017; 123: 2054-60
5. Venables Z, Autier P, Nijsten T, et al. Nationwide incidence of metastatic cutaneous squamous cell carcinoma in England. *JAMA Dermatol* 2018 Nov 28. doi: 10.1001/jamadermatol. 2018. 4219
6. Lipson EJ, Bagnasco SM, Moore J Jr, et al. Tumor Regression and Allograft Rejection after Administration of Anti-PD-1. *N Engl J Med* 2016; 374(9): 896-8
7. Chae YK, Galvez C, Anker JF, Iams WT, Bhave M. Cancer immunotherapy in a neglected population: The current use and future of T-cell-mediated checkpoint inhibitors in organ transplant patients. *Cancer Treat Rev* 2018 Feb; 63:116-121.
8. Ad Hoc Task Force, Connolly SM, Baker DR, et al. AAD/ACMS/ASDSA/ASMS 2012 appropriate use criteria for Mohs micrographic surgery: a report of the American Academy of Dermatology, American College of Mohs Surgery, American Society for Dermatologic Surgery Association, and the American Society for Mohs Surgery. *J Am Acad Dermatol* 2012; 67(4): 531-50.
9. Goldenberg A, Ortiz A, Kim SS, Jiang SB. Squamous cell carcinoma with aggressive subclinical extension: 5-year retrospective review of diagnostic predictors. *J Am Acad Dermatol* 2015; 73(1):120-6

10. Song SS, Goldenberg A, Ortiz A, Eimpunth S, Oganesyany G, Jiang SI. Nonmelanoma Skin Cancer with Aggressive Subclinical Extension in Immunosuppressed Patients. *JAMA Dermatol* 2016; 152(6): 683-90
11. Levin EC, Chow C, Makhzoumi Z, Jin C, Shiboski SC, Arron ST. Association of Postoperative Antibiotics with Surgical Site Infection in Mohs Micrographic Surgery. *Dermatol Surg* 2019; 45(1): 52-57
12. Brewer JD, Otley CC, Christenson LJ, Phillips PK, Roenigk RK, Weaver AL. The effects of sirolimus on wound healing in dermatologic surgery. *Dermatol Surg* 2008 Feb; 34(2): 216-23
13. Veness MJ, Morgan GJ, Palme CE, Gebiski V. Surgery and adjuvant radiotherapy in patients with cutaneous head and neck squamous cell carcinoma metastatic to lymph nodes: Combined treatment should be considered best practice. *Laryngoscope* 2005; 115: 870-5
14. Chockalingam R, Downing C, Tyring SK. Cutaneous squamous cell carcinomas in organ transplant recipients. *J Clin Med* 2015; 4:1229–39
15. Zwald FO, Brown M. Skin cancer in solid organ transplant recipients: advances in therapy and management, part II: management of skin cancer in solid organ transplant recipients. *J Am Acad Dermatol* 2011; 65(2): 263-279
16. Bangash HK, Colegio OR. Management of non-melanoma skin cancer in immunocompromised solid organ transplant recipients. *Curr Treat Options Oncol* 2012; 13:354–76
17. O'Donovan P, Perrett CM, Zhang X, et al. Azathioprine and UVA light generate mutagenic oxidative DNA damage. *Science* 2005; 309: 1871-4
18. Euvrard S, Morelon E, Rostaing L, et al. Sirolimus and secondary skin-cancer prevention in kidney transplantation. *N Engl J Med* 2012; 367: 329–39
19. den Akker JMH-v, Harden PN, Hoitsma AJ, et al. Two-year randomized controlled prospective trial converting treatment of stable renal transplant recipients with cutaneous invasive squamous cell carcinomas to sirolimus. *J Clin Oncol* 2013; 31: 1317–23
20. Dantal J, Morelon E, Rostaing L, et al; TUMORAPA Study Group. Sirolimus for Secondary Prevention of Skin Cancer in Kidney Transplant Recipients: 5-Year Results. *J Clin Oncol* 2018; 36(25): 2612-20

21. Harwood CA, Leedham-Green M, Leigh IM, Proby CM. Low-dose retinoids in the prevention of cutaneous squamous cell carcinomas in organ transplant recipients: a 16-year retrospective study. *Arch Dermatol* 2005; 141: 456-464
22. Que SKT, Zwald FO, Schmults CD. Cutaneous squamous cell carcinoma: Management of advanced and high-stage tumors. *J Am Acad Dermatol* 2018; 78: 249-261
23. Breithaupt AD, Beynet D, Soriano T. Capecitabine for squamous cell carcinoma reduction in solid organ transplant recipients. *J Am Acad Dermatol Case Rep* 2015;1(6): S16-8
24. Endrizzi B, Ahmed RL, Ray T, et al. Capecitabine to reduce nonmelanoma skin carcinoma burden in solid organ transplant recipients. *Dermatol Surg* 2013; 39: 634–45
25. Chen AC, Martin AJ, Choy B, et al. A phase 3 randomized trial of nicotinamide for skin-cancer chemoprevention. *N Engl J Med* 2015; 373: 1618–26
26. Chen AC, Martin AJ, Dalziel RA, et al. A phase II randomized controlled trial of nicotinamide for skin cancer chemoprevention in renal transplant recipients. *Br J Dermatol* 2016; 75: 1073–5
27. Krisl JC, Doan VP. Chemotherapy and Transplantation: The Role of Immunosuppression in Malignancy and a Review of Antineoplastic Agents in Solid Organ Transplant Recipients. *Am J Transplant* 2017; 17(8): 1974-91
28. Leard LE, Cho BK, Jones KD, et al. Fatal diffuse alveolar damage in two lung transplant patients treated with cetuximab. *J Heart Lung Transplant* 2007; 26(12): 1340-4
29. Zehou O, Leibler C, Arnault JP, et al. Ipilimumab for the treatment of advanced melanoma in six kidney transplant patients. *Am J Transplant* 2018; 18(12): 3065-71
30. Aguirre LE, Guzman ME, Lopes G, Hurley J. Immune Checkpoint Inhibitors and the Risk of Allograft Rejection: A Comprehensive Analysis on an Emerging Issue. *Oncologist* 2019; 24(3): 394-401
31. Ducroux E, Martin C, Bouwes Bavinck JN, et al. Risk of aggressive skin cancers after kidney retransplantation in patients with previous posttransplant cutaneous squamous cell carcinomas: A retrospective study of 53 cases. *Transplantation* 2017; 101(4): e133-e141